24/7 Market News Snapshot 11 December, 2024 – Relay Therapeutics, Inc. Common Stock (NASDAQ:RLAY)

December 11, 2024

DENVER, Colo., 11 December, 2024 (247marketnews.com) – (Nasdaq:RLAY) are discussed in this article.
Relay Therapeutics, Inc. (Nasdaq:RLAY) has experienced a notable surge in trading activity today, opening at $4.90 before climbing to around $4.895, reflecting an increase of approximately 10.50%. This uptick follows a previous session close at $4.43, indicating strong investor interest as evident from a trading volume of 8.55 million shares. Technical indicators suggest potential for further gains while cautioning traders to monitor resistance levels and market trends carefully.

In conjunction with its market performance, Relay Therapeutics has announced encouraging developments from its clinical trials of RLY-2608, an investigational therapy targeting PI3Kα mutations for patients with HR+/HER2- metastatic breast cancer. Recently presented interim data at the 2024 San Antonio Breast Cancer Symposium revealed a median progression-free survival (PFS) of 11.4 months for patients receiving RLY-2608 in combination with fulvestrant, signaling a significant efficacy enhancement compared to current standards.

Notably, the confirmed objective response rate among patients with kinase mutations was reported at an impressive 67%, supporting the potential of this novel allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor. Dr. Don Bergstrom, President of R&D at Relay Therapeutics, expressed optimism regarding these results, particularly as the company gears up for a pivotal study slated to commence in 2025.

Moreover, the ongoing ReDiscover study aims to further evaluate RLY-2608 in various combinations, including ribociclib and the newly introduced atirmociclib regimen. The company’s innovative Dynamo® platform underscores its commitment to addressing previously difficult targets in oncology. With approximately $840 million in cash reserves reported as of Q3 2024, Relay Therapeutics is well-positioned to advance its research and development initiatives, including anticipated Phase 1/2 data disclosures and pivotal studies targeting both breast cancer and vascular malformations in the near future.

Related news for (RLAY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.